XENEHealthcare · BiotechnologyThe 19 Wall Street analysts covering Xenon Pharmaceuticals, Inc. hold a median 12-month price target of $74 — +104.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 21 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Xenon Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (93): The share price has been relatively steady.
Growth (27): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on XENE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +104.5% from it.
Of the 20 most recent actions, 1 moved their price target up and 7 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Oct 2026 | Guggenheim | Assumes | Buy | $73 |
| 18 Sept 2026 | Baird | Maintains | Outperform | — |
| 18 Sept 2026 | Baird | Maintains | Outperform | $97 → $90 |
| 18 Sept 2026 | Deutsche Bank | Downgrade | Hold | $90 → $46 |
| 18 Sept 2026 | Deutsche Bank | Downgrade | Hold | — |
| 18 Sept 2026 | Needham | Maintains | Buy | — |
| 18 Sept 2026 | Needham | Maintains | Buy | $78 → $60 |
| 18 Sept 2026 | RBC Capital | Maintains | Outperform | — |
| 18 Sept 2026 | RBC Capital | Maintains | Outperform | $81 → $70 |
| 18 Sept 2026 | Wedbush | Maintains | Outperform | — |
| 18 Sept 2026 | Wedbush | Maintains | Outperform | $71 → $55 |
| 18 Sept 2026 | Wells Fargo | Maintains | Overweight | $69 → $64 |
| 18 Sept 2026 | Wells Fargo | Maintains | Overweight | — |
| 7 Aug 2026 | RBC Capital | Maintains | Outperform | $82 → $81 |
| 7 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 27 May 2026 | JP Morgan | Maintains | Overweight | $80 → $82 |
| 27 May 2026 | JP Morgan | Maintains | Overweight | — |
| 12 May 2026 | JP Morgan | Maintains | Overweight | — |
| 8 May 2026 | Needham | Maintains | Buy | — |
| 8 May 2026 | RBC Capital | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
XENE appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 21 Oct 2026, Xenon Pharmaceuticals, Inc. returned −16.5% against +16.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 93% of US stocks
Cheaper than 2% of US stocks
Cheaper than 33% of US stocks
Cheaper than 82% of US stocks
Higher than 1% of US stocks
Higher than 3% of US stocks
Higher than 30% of US stocks
Higher than 23% of US stocks
Higher than 15% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Xenon Pharmaceuticals, Inc. has a market value of $3.5B and an enterprise value of $2.6B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$409.2M.
Diluted earnings per share, trailing twelve months: $−4.74.
Free cash flow in the twelve months to 30 June 2026: −$338.5M.
Trailing P/E: −8.2×; forward P/E: −7.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Xenon Pharmaceuticals, Inc. employs 358 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Xenon Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Xenon paused enrollment in its late-stage depression trials after unexpected side effects. The item also notes potential growth from the company’s epilepsy pipeline.
Why it matters — The pause affects the depression program, while the epilepsy pipeline remains relevant to XENE watchers assessing the company’s development portfolio.
Xenon Pharmaceuticals announced equity inducement grants to eight new non-officer employees, consisting of 17,850 share options and 10,500 restricted share units. The grants were approved by the Compensation Committee with an effective date of October 1, 2026, and were issued under Nasdaq Listing Rule 5635(c)(4).
Why it matters — This signals the company is hiring new personnel, which XENE watchers may track as a routine corporate announcement related to employee retention and onboarding.
Defence Therapeutics announced the appointment of finance executive Sherry Aulin to its Board of Directors, where she will also serve as a member of the company's Audit Committee. The announcement was made on September 29, 2026.
Why it matters — This news concerns Defence Therapeutics, a separate biotechnology company, and has no direct bearing on Xenon Pharmaceuticals' operations or outlook.
Xenon Pharmaceuticals has filed its first new drug application for azetukalner as a treatment for focal-onset seizures. The company has also paused portions of its late-stage psychiatry program to evaluate changes intended to improve tolerability.
Why it matters — A XENE watcher would care because the NDA filing advances azetukalner's regulatory path while the psychiatry trial pause signals a potential shift in the drug's development timeline.
SBS Law announced that Xenon Pharmaceuticals Inc. (XENE) investors have an opportunity to join a fraud investigation into the company. The announcement was made via a Business Wire release from Los Angeles.
Why it matters — A fraud investigation could signal potential legal or regulatory exposure for Xenon Pharmaceuticals, which XENE watchers would want to monitor.
The 19 Wall Street analysts covering Xenon Pharmaceuticals, Inc. have a median 12-month price target of $74, with estimates ranging from $46 to $90. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 19 analysts covering Xenon Pharmaceuticals, Inc., 18 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Xenon Pharmaceuticals, Inc. 38 out of 100 across roughly 4,600 US stocks as at 21 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 21 Oct 2026, Xenon Pharmaceuticals, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (93 of 100).
No one can know that. What the data says: the median 12-month target from 19 analysts implies +104.5% from the last close, and Ticker Nerd's factor model ranks Xenon Pharmaceuticals, Inc. 38 out of 100 as at 21 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Xenon Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XENE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $46 to $90 over the next 12 months.
Xenon Pharmaceuticals, Inc. returned -16.5% over the 12 months to 21 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company that develops therapies for neurological and psychiatric disorders.
The most recent item we track (Zacks Investment Research, 15 Oct 2026): "XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?". Xenon paused enrollment in its late-stage depression trials after unexpected side effects. The item also notes potential growth from the company’s epilepsy pipeline.
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company that develops therapies for neurological and psychiatric disorders. Xenon Pharmaceuticals Inc. concentrates on ion channel science and small-molecule drug discovery, with a pipeline centered on treatments for epilepsy and other central nervous system conditions. Its current programs include late-stage and early-stage candidates aimed at focal seizures, primary generalized tonic-clonic seizures, major depressive disorder, bipolar depression, and pain. The company operates as a single reportable segment focused on discovering, developing, and delivering therapeutics for patients with high unmet medical needs. Headquartered in Burnaby, British Columbia, Xenon Pharmaceuticals Inc. has an operating presence in North America and collaborates with clinical and research partners to advance its development programs.
CEO Mr. Ian C. Mortimer C.M.A., CPA, M.B.A. · 358 employees · Canada · https://www.xenon-pharma.com
